Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Accumulating epidemiological evidence shows that obesity is associated with an increased risk of several types of adult cancers, including endometrial cancer. Chronic hyperinsulinemia, a typical hallmark of diabetes, is one of the leading factors responsible for the obesity-cancer connection. Numerous cellular and circulating factors are involved in the biochemical chain of events leading from hyperinsulinemia and insulin resistance to increased cancer risk and, eventually, tumor development. Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes. Recently, metformin was shown to exhibit anti-proliferative effects in ovarian and Type I endometrial cancer, although the mechanisms responsible for this non-classical metformin action remain unclear. The insulin-like growth factors (IGFs) play a prominent role in cancer biology and their mechanisms of action are tightly interconnected with the insulin signaling pathways. Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma (USC) are potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Our results show that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of USC cell lines with both wild type and mutant p53. Taken together, our results suggest that metformin therapy could be a novel and attractive therapeutic approach for human USC, a highly aggressive variant of endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin is shown to decrease insulin and IGF-1 levels and downregulate IIS in cancer cells”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Sarfstein et al. 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sarfstein, R., Belfiore, A., & Werner, H. (2010) · Cancers · doi:10.3390/cancers2020233 · Cited by 31 · cited 2×
“USPC-1 and USPC-2 cells were transfected as previously described [28,29].”
BackgroundMethodSelf-citationRetractedp53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“Part of these, seemingly, paradoxical results can be explained by the fact that Ishikawa cells are known to have mutations in the ras protooncogene, p53 [45] and pTen tumor suppressor gene, leading to constitutive phosphorylation of AKT [46].”
ResultThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 2×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundRole of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“In vitro and in vivo studies showed increased peripheral insulin sensitivity and cancer growth inhibition by Ampk activation [27].”
BackgroundDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 1×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · cited 1×
“cell proliferation in a number of experimental systems [12–15].”
BackgroundA Detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis
Vindeløv, L. L., Christensen, I. J., & Nissen, N. I. (1983) · Cytometry · doi:10.1002/cyto.990030503 · Cited by 1,639
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundObesity, endogenous hormones, and endometrial cancer risk: a synthetic review.
Kaaks, R., Lukanova, A., & Kurzer, M. S. (2002) · PubMed · Cited by 1,181
Research works printed but not linked: 1
- I Bruchim, 2009, Targeting the IGF1 axis in cancer proliferation, Expert Opin Ther Targets, 13, 1179, 10.1517/14728220903201702 · DOI
Cited by
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
“Metformin is reported to downregulate expression of insulin and IGF-1 receptors (230, 231) and reduces phosphorylation of insulin receptors (232) including IRS-1 (230, 233).”
BackgroundPolycystic ovary syndrome current status and future perspective
Naz, R. K. (2014) · Frontiers in Bioscience · doi:10.2741/e695 · Cited by 259
Wang, Y., Xu, W., Yan, Z., Zhao, W., Mi, J., Li, J., & Yan, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0731-5 · Cited by 254
“In uterine serous carcinoma (USC), the antiproliferative action of metformin is mediated by suppression of the IGF-1 receptor pathway [20].”
Yan, L., Zhou, J., Gao, Y., Ghazal, S., Lu, L., Bellone, S., Yang, Y., Liu, N., Zhao, X., Santin, A. D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.236 · Cited by 208
Metadata
- Authors
- Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H.
- Affiliations
- Tel Aviv University (IL)
- Meir Medical Center (IL)
- Corresponding author
- Werner, Haim
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e61537
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3631250
- OpenAlex
- W2009665800
- Cited by
- 150
- References
- 58
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 14 · 2018: 11 · 2017: 10 · 2016: 16 · 2015: 11 · 2014: 22 · 2013: 3
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, uterine serous carcinoma, IGF-1 receptor, p53, apoptosis, cell proliferation, cell migration, endometrial cancer, hyperinsulinemia, biguanides
- MeSH terms
- Forkhead Box Protein O1, Glycogen Synthase Kinase 3 beta, Adenylate Kinase, Cell Cycle, Cell Movement, Cell Survival, Female, Humans, Insulin, Insulin-Like Growth Factor I, Metformin, Phosphorylation, Promoter Regions, Genetic, Receptor, Insulin, Uterine Neoplasms, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Endometrial Neoplasms, Apoptosis, Receptor, IGF Type 1, Cystadenocarcinoma, Serous, Glycogen Synthase Kinase 3, Cell Line, Tumor, Cell Proliferation, Forkhead Transcription Factors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners. https://app.cochat.ai/papers/10.1371/journal.pone.0061537
- The paper
- Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H. (2013). Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners. PLoS ONE. https://doi.org/10.1371/journal.pone.0061537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.